This article is more than 5 years old. Information may no longer be current.

Alcon announces Q2 results

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Global sales for Alcon Inc. increased almost 12% during the second quarter of 2006, the company announced.

For the second quarter, which ended June 30, global sales increased 11.8% to $1.31 billion over the second quarter of last year, Cary Rayment, Alcon CEO, chairman and president, said during a conference call with investors.

Spurred by IOL sales growth, Alcon’s surgical business grew faster than the overall market in both unit and dollar sales. Surgical sales grew 8.9% to $567.4 million and IOL sales grew 16.7%.

Total pharmaceutical sales increased 11.3% to $559.9 million, due to increased sales of the glaucoma medications Travatan (travoprost) and Azopt (brinzolamide). Consumer product sales increased 23.8% to $183.9 million. Contact lens solution sales grew 38.1%, which was driven by the success of Opti-Free RepleniSH and the withdraw of a competitive lens solution.

The company sustained net earnings of $465.6 million, or $1.50 per share for the quarter, with an adjusted earnings per share increase of 17.3%.